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ABSTRACT 
Objective: Tamoxifen is the drug of choice to treat breast cancer positive for estrogen receptor. Long-term use of tamoxifen can induce multidrug 
resistance (MDR) associated with decreased sensitivity of cancer cells to the drug. One of the causes of MDR is overexpression of efflux transporter 
multidrug resistance-associated protein (MRP)2. Various drugs are known to act as MRP2 inhibitors, including curcumin. This study investigated 
the effects of curcumin on the sensitivity of breast cancer cells to tamoxifen through inhibition of MRP2.  
Methods: We used MCF-7 cells that were previously exposed to long-term tamoxifen treatment [MCF-7(T) cells]. MCF-7(T) cells were treated with 
1 µM tamoxifen, curcumin (5, 10, and 20 µM), combinations of curcumin (5, 10, and 20 µM) and 1 µM tamoxifen, or 10 µM nevirapine (a known 
MRP2 inhibitor) for 5 d. Then, the cells were harvested, counted to assess cell viability, and evaluated for MRP2 mRNA expression.  
Results: Treatment with curcumin alone or in combination with tamoxifen significantly reduced cell viability at all curcumin concentrations 
compared with the control. The reduction in cell viability was accompanied by a reduced level of MRP2 mRNA expression. 
Conclusion: Application of curcumin to MCF-7 cells previously exposed to long-term tamoxifen treatment increase the sensitivity of cancer cells to 
tamoxifen
Keywords: Curcumin, Tamoxifen, MRP2, Multidrug resistance 
. The increased sensitivity of these cells was attributed, at least in part, to inhibition of the efflux transporter MRP2. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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INTRODUCTION 
Tamoxifen is the drug of choice for estrogen-receptor-positive 
breast cancer treatment. Tamoxifen competes with estrogen for 
binding to the estrogen receptor [1]. Many patients who chronically 
use tamoxifen will eventually develop tamoxifen resistance. 
Resistance is a common clinical problem that leads to unsuccessful 
treatment. 
The issue impeding successful cancer treatment is development of 
multidrug resistance (MDR) against tamoxifen. MDR against 
chemotherapy is the phenomenon of resistance after long-term 
exposure to anticancer agents [3]. Several mechanisms have been 
proposed to mediate MDR in cancer cells. The mechanisms include 
loss of a cell surface receptor; specific metabolism of a drug; 
alteration by mutation of the specific target of the drug; and 
alterations in apoptosis and cell cycle processes as well as drug 
transporters. Alterations in drug transporters can limit 
accumulation of drugs within cells by limiting uptake and enhancing 
drug efflux [4]. One of the most common factors implicated in MDR 
is ATP-binding cassette (ABC) transporters; a family of membrane 
proteins characterized by homologous ATP-binding and 
transmembrane domains, which are a component of the energy-
dependent efflux transport system [5]. ABC transporters include P-
glycoprotein, breast cancer resistance protein (BCRP), and 
multidrug resistance-associated protein (MRP) 2 that play major 
roles in tamoxifen resistance [3]. 
Long-term use of tamoxifen reduces the sensitivity of 
cancer cells to tamoxifen [2]. 
Among these ABC transporters, expression of MRP2 increases in 
breast cancer cells because of long-term tamoxifen use. An approach 
to overcome this problem is to reduce excessive expression of the 
MRP2 transporter by administering MRP2 inhibitors. 
To date, no drug targeting MDR has been clinically approved for 
cancer treatment. A new promising approach to enhance 
chemosensitivity in MDR cases is to inhibit the ABC efflux 
transporter. Several in vitro studies have shown that some drugs 
that inhibit the MRP2 transporter enhance the sensitivity of cancer 
cells to anticancer drugs [6]. Such drugs, such as indomethacin, 
ketoprofen, probenecid, and reserpine, can cause some side effects if 
used long term. Alternatives with minimal side effects are natural 
compounds. Such natural compounds include flavonoids, such as 
myricetin, curcumin, and quercetin, which inhibit many ABC 
transporters [7]. These compounds have not been tested for their 
efficacy in tamoxifen-resistant cancer cases. 
Curcumin is the active polyphenolic compound in ginger and 
turmeric that is common in Indonesia. Turmeric contains 
curcuminoid consisting of curcumin, dihydrocurcumin, 
desmethoxycurcumin, and bisdemethoxycurcumin [8]. Curcumin 
has potent effects, such as anti-inflammatory, antioxidant, and 
anticancer effects. The anticancer activity of curcumin induces 
apoptosis, inhibits activation of nuclear factor κB, and decreases the 
levels of proinflammatory cytokines (interleukin-6, interleukin-8, 
and tumor necrosis factor) [9]. In addition, tetrahydrocurcumin, a 
major metabolite of curcumin, inhibited the efflux function of P-
glycoprotein, MXR, and MRP1 in an in vitro study related to cancer 
[10]. In this study, we investigated the effects of curcumin on the 
sensitivity of breast cancer cells to tamoxifen through inhibition of 
efflux transporter MRP2. A reduction in MRP2 mRNA expression is 
expected to reduce the amount of tamoxifen effluxed from cancer 
cells to increase the effectiveness of breast cancer therapy and 
decrease tamoxifen resistance. 
MATERIALS AND METHODS  
Materials 
The MCF-7 cell line was obtained from The Agency for the 
Assessment and Application of Technology (Serpong, Indonesia). 
Dulbecco’s modified Eagle’s medium, fetal bovine serum, 
penicillin/streptomycin, and Fungizone were purchased from Gibco 
Ltd. (Singapore). Curcumin, nevirapine, and dimethylsulfoxide were 
purchased from Sigma–Aldrich (Singapore). Tripure isolation 
reagents and a LightCycler RNA Master SYBR Green I kit were 
purchased from Roche Diagnostics (Singapore). Primers were 
purchased from 1st BASE Ltd. (Singapore). 
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We used MCF7 cells that were previously exposed to long-term 
tamoxifen treatment 
Treatment of MCF-7(T) cells with curcumin 
[MCF-7(T) cells] [11]. MCF-7(T) cells were 
cultured in medium described in a previous study [11]. These cells 
were subcultured at 90% confluence. The medium was changed 
every day.  
MCF-7 (T) cells were treated with 1 µM tamoxifen combined with 
curcumin (5, 10, and 20 µM), and 10 µM nevirapine for 5 d. 
RNA isolation 
Nevirapine was used as a positive control for an MRP2 inhibitor. 
Tamoxifen, curcumin, and nevirapine were prepared in dimethyl 
sulfoxide. The medium was changed every day. Cells were harvested 
at 5 d after drug administration. Then, cell viability was analyzed by 
the trypan blue exclusion method. RNA was then isolated to quantify 
mRNA expression by quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR).  
RNA isolation was performed using Tripure Isolation Reagents 
(Roche). The quantity of RNA was determined using a UV 
spectrophotometer at an absorbance of 260 nm. The RNA purity 
index was determined by calculating the ratio of UV absorption at 
260 and 280 nm.  
qRT-PCR 
To analyze mRNA expression by qRT-PCR, 500 ng of RNA template 
was used.
Data analysis 
 The mRNA expression of MRP2 was quantified by qRT-
PCR using a kit and primers as described previously [11, 12]. We 
calculated the expression level of MRP2 mRNA using the Livak 
method [13]. 
Data are presented as mean±standard deviation (SD). Graphs were 
created using GraphPad 7 Prism software. Differences between 
groups were determined using one-way ANOVA followed by the 
Tukey post-hoc test. p<0.05 was considered as significant.  
RESULTS  
After 5 d of treating MCF7 (T) cells, curcumin increased the sensitivity 
of cells to tamoxifen (fig. 1). Curcumin at the highest concentration (20 
µM) significantly reduced the percentage of viable cells (fig. 1). 
 
 
Fig. 1: Percentages of viable MCF-7 (T) cells after 5 d of 
tamoxifen treatment with or without curcumin or nevirapine. 
Results are presented as the mean ± SD (N=4),
 
 *p<0.05 versus 
MCF7 (T) cells. **p<0.001 versus MCF7 (T) cells 
MRP2 mRNA expression was measured after 5 d of treatment. The 
addition of curcumin to tamoxifen reduced mRNA expression of 
MRP2 in MCF-7 (T) cells (fig. 2). Curcumin at the highest 
concentration (20 µM) and 10 µM nevirapine as the positive control 
resulted in a significant reduction of MRP2 mRNA expression (fig. 2). 
 
 
Fig. 2: MRP2 mRNA expression after MCF-7 (T) cells were 
treated with 1 µM tamoxifen, tamoxifen with 5, 10 and 20 µM 
curcumin, or 10 µM nevirapine for 5 d. Results are presented as 
the mean ± SD (N=4)
 
. **p<0.001 versus MCF-7 (T) cells 
DISCUSSION 
One of the causes of MDR is overexpression of drug transporters 
such as MRP2, which can increase efflux of anticancer drugs from 
cancer cells, thereby contributing to the failure of chemotherapy 
[14]. Choi et al. [15] found that tamoxifen-resistant MCF7 cells 
express a high level of MRP2 mRNA. The high MRP2 expression in 
tamoxifen-resistant MCF7 cells may result from activation of 
pregnane-X receptor (PXR). Their study showed that PXR activation 
during tamoxifen resistance is crucial to regulate MRP2 mRNA 
expression. In addition, they found that PI3-kinase plays a role in 
controlling MRP2 expression of tamoxifen-resistant MCF7 cells. 
Another study showed that expression of MRP2 in MCF-7 cells was 
increased after tamoxifen treatment for 10 passages (44 d) [11].  
In this study, we exposed tamoxifen-resistant MCF7 cells to 
curcumin at various concentrations (5, 10, and 20 µM) or the 
positive control (10 µM nevirapine) combined with 1 µM tamoxifen. 
Curcumin at the lowest concentration did not reduce the percentage 
of viable cells, whereas curcumin at the highest concentration 
significantly reduced viable cells compared with the positive control 
(nevirapine). Nevirapine is a non-nucleoside reverse transcriptase 
inhibitor that inhibits MRP2 in vitro. Cytotoxic effects of nevirapine 
against cancer cell lines have been reported previously [16]. 
Curcumin is also associated with chemoprevention by inhibiting 
MDR1, MRP, and BCRP efflux transporters [17].  
Jiang et al. [18] showed that the combination of tamoxifen and 
curcumin in MCF7/lCC2 cells for 3 d had a synergistic effect by 
decreasing cell viability, and curcumin increased the sensitivity of 
the cells to tamoxifen.  
Their study also showed that curcumin modulated cell proliferation 
and increased sensitivity of resistant breast cancer cells positive for 
the estrogen receptor to long-term tamoxifen exposure. Wortelboer 
et al. [19] showed that 50 µM curcumin inhibited MRP1 and MRP2 
transporters in MDCKII-MRP1 and MDCKII-MRP2 cells. The 
mechanism of MRP transporter inhibition by curcumin is still 
unclear. Presumably, the polyphenol content in curcumin modulates 
the transport processes of MRP1 and MRP2 through several 
mechanisms, such as the formation of a glutathione (GSH) conjugate 
that competitively inhibits MRP1 and MRP2, a decrease in GSH 
levels, and direct inhibition of MRP1 and MRP2 through MRP–
curcumin interactions [19]. 
Based on our results, we believe that curcumin might be a promising 
candidate agent to reverse tamoxifen resistance in breast cancer 
cells with MRP2 as the target. Further research on the mechanism of 
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curcumin in decreasing mRNA expression of MRP2 in breast cancer 
cells with long term tamoxifen treatment is still needed.  
CONCLUSION 
Curcumin at high concentrations can be a chemosensitizer for 
tamoxifen therapy. The increase in sensitivity of our cells was 
attributed to, at least in part, inhibition of the efflux transporter 
MRP2. 
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